Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Personalized medicine approaches in epilepsy.

Journal of internal medicine - 1 Feb 2015

Walker L E, Mirza N, Yip V L M, Marson A G, Pirmohamed M

Abstract excerpt

Epilepsy affects 50 million persons worldwide, a third of whom continue to experience debilitating seizures despite optimum anti-epileptic drug (AED) treatment. Twelve-month remission from seizures is less likely in female patients, individuals aged 11-36 years and those with neurological insults and shorter time between first seizure and starting treatment. It has been found that the presence of multiple...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticonvulsants
Share to Epilepsy
Share to Global Health

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HLA-A Antigens

Share to HLA-B Antigens

Share to NAV1.1 Voltage-Gated Sodium Channel

Share to Precision Medicine

Share to Stevens-Johnson Syndrome

Source

Identifiers

PMID: 25338670
DOI: 10.1111/joim.12322

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Personalized medicine approaches in epilepsy.PMID 25338670Read ↗

The pharmacogenomics of epilepsySemantic proximity Read ↗

HLA genotype testing for carbamazepine, oxcarbazepine and eslicarbazepine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).Semantic proximity Read ↗

Risk-conferring HLA variants in an epilepsy cohort: benefits of multifaceted use of whole genome sequencing in clinical practice.Semantic proximity Read ↗

Neurogenetic biomarkers in epilepsy: A comprehensive narrative review of progression and therapeutic approaches.Semantic proximity Read ↗

Pharmacogenetics of Drug-Resistant Epilepsy (Review of Literature)Semantic proximity Read ↗

Pharmacogenetics of anti-seizure medications in Arab countries: a comprehensive reviewSemantic proximity Read ↗

Pharmacogenomics and epilepsy: the road ahead.Semantic proximity Read ↗

The complex etiology of Epilepsy in the Middle East: Genetic analysis and HLA associationsSemantic proximity Read ↗

The clinical impact of pharmacogenetics on the treatment of epilepsy.Semantic proximity Read ↗

HLA-A*31:01 and Oxcarbazepine-Induced DRESS in a Patient With Seizures and Complete DCX Deletion.Semantic proximity Read ↗

Integrated Mendelian Randomization and Single‐Cell Transcriptomics Analysis Identifies Critical Blood Biomarkers and Potential Mechanisms in EpilepsySemantic proximity Read ↗

Pharmacogenetics of antiepileptic drug-induced hypersensitivity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.